Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment

Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment

Systemic treatment of malignant pleural mesothelioma (MPM) is moderately active for the intrinsic pharmacological resistance of MPM cell and its ability to induce an immune suppressive environment. Here we showed that the expression of bromodomain (BRD) proteins BRD2, BRD4 and BRD9 was significantly...

Full description

Bibliographic Details
Main Authors: Chiara Riganti, Marcello Francesco Lingua, Iris Chiara Salaroglio, Chiara Falcomatà, Luisella Righi, Deborah Morena, Francesca Picca, Daniele Oddo, Joanna Kopecka, Monica Pradotto, Roberta Libener, Sara Orecchia, Paolo Bironzo, Valentina Comunanza, Federico Bussolino, Silvia Novello, Giorgio Vittorio Scagliotti, Federica Di Nicolantonio, Riccardo Taulli
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:OncoImmunology
Subjects:
bromodomain inhibitors
immunogenic cell death
immune checkpoints
malignant pleural mesothelioma
myeloid-derived suppressor cells
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1398874

Internet

http://dx.doi.org/10.1080/2162402X.2017.1398874

Similar Items